Sun Pharmaceutical Industries plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price.
The drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
The company announced the U. S. launch of the website for its long-term care (LTC) division, www.sunltc.com.
The new website presents Sun Pharma's LTC portfolio of alternative formulation products and underscores Sun Pharma's commitment to meeting the needs of the up to 40% of American adults who cannot or will not swallow solid medication forms.
The stock was trading at Rs.616.50 ,higher by 15.05 points or 2.50% which was opened at Rs.606.40 as against the previous close of Rs.601.45.It hit 52 weeks high of Rs.654.40 and low of 312.00.